Amedisys Inc (AMED) Given Consensus Rating of “Hold” by Brokerages
Shares of Amedisys Inc (NASDAQ:AMED) have received a consensus recommendation of “Hold” from the ten research firms that are presently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $56.14.
A number of equities research analysts recently issued reports on AMED shares. Zacks Investment Research downgraded shares of Amedisys from a “buy” rating to a “hold” rating in a research note on Tuesday, May 2nd. Jefferies Group LLC reaffirmed a “buy” rating and set a $57.00 price target on shares of Amedisys in a research note on Friday, April 28th. Mizuho raised shares of Amedisys from a “neutral” rating to a “buy” rating and set a $65.00 price target on the stock in a research note on Wednesday, May 3rd. Royal Bank Of Canada reaffirmed a “hold” rating and set a $56.00 price target on shares of Amedisys in a research note on Monday, June 5th. Finally, Stephens upped their price target on shares of Amedisys from $50.00 to $54.00 and gave the company an “equal weight” rating in a research note on Thursday, May 4th.
ILLEGAL ACTIVITY WARNING: “Amedisys Inc (AMED) Given Consensus Rating of “Hold” by Brokerages” was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/12/amedisys-inc-amed-given-consensus-rating-of-hold-by-brokerages.html.
Amedisys (NASDAQ:AMED) traded up 1.35% during mid-day trading on Friday, hitting $48.88. 352,034 shares of the stock traded hands. The company’s 50 day moving average is $56.08 and its 200 day moving average is $54.19. Amedisys has a 12 month low of $34.58 and a 12 month high of $65.91. The company has a market cap of $1.66 billion, a P/E ratio of 41.78 and a beta of 0.89.
Amedisys (NASDAQ:AMED) last issued its earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.12. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. The firm had revenue of $378.80 million during the quarter, compared to analyst estimates of $380.80 million. During the same quarter in the prior year, the business earned $0.42 earnings per share. Amedisys’s revenue for the quarter was up 5.0% on a year-over-year basis. On average, analysts expect that Amedisys will post $2.21 earnings per share for the current fiscal year.
In related news, insider David B. Pearce sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $50.00, for a total value of $50,000.00. Following the transaction, the insider now owns 10,488 shares of the company’s stock, valued at approximately $524,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Bruce D. Perkins purchased 500 shares of Amedisys stock in a transaction that occurred on Thursday, May 25th. The stock was bought at an average cost of $59.69 per share, for a total transaction of $29,845.00. Following the purchase, the director now directly owns 13,331 shares in the company, valued at $795,727.39. The disclosure for this purchase can be found here. Corporate insiders own 2.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Federated Investors Inc. PA increased its position in Amedisys by 2.3% in the second quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock valued at $122,000 after buying an additional 44 shares in the last quarter. State of Alaska Department of Revenue increased its position in Amedisys by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 3,080 shares of the health services provider’s stock valued at $157,000 after buying an additional 70 shares in the last quarter. State Board of Administration of Florida Retirement System increased its position in Amedisys by 0.5% in the second quarter. State Board of Administration of Florida Retirement System now owns 19,658 shares of the health services provider’s stock valued at $1,235,000 after buying an additional 93 shares in the last quarter. Suntrust Banks Inc. increased its position in Amedisys by 2.0% in the first quarter. Suntrust Banks Inc. now owns 5,465 shares of the health services provider’s stock valued at $279,000 after buying an additional 107 shares in the last quarter. Finally, Municipal Employees Retirement System of Michigan increased its position in Amedisys by 1.8% in the first quarter. Municipal Employees Retirement System of Michigan now owns 6,370 shares of the health services provider’s stock valued at $325,000 after buying an additional 110 shares in the last quarter. 99.80% of the stock is currently owned by institutional investors.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.